Aptadir Therapeutics, a Milan, Italy-based biotech company developing RNA inhibitor-based therapeutics for treating intractable cancers and genetic conditions, raised $1.6M in Pre-Seed funding.
EXTEND provided the funding.
The company intends to use the funds to optimize its lead asset, Aptadir Ce-49.
Founded by Dr Annalisa Di Ruscio and Dr Vittorio De Franciscis alongside Prof. Daniel Tenen, and Prof. Marcin Kortylewski, Aptadir Therapeutics is a preclinical biotech company developing a new class of RNA therapeutics. Its therapeutic focus is underserved intractable cancers and genetic conditions, including underserved intractable conditions in the oncology and rare diseases fields such as myelodysplastic syndrome and fragile X syndrome.
The first program in development is a treatment for myelodysplastic neoplasms (MDS), a group of blood cancers that occur when immature blood cells in the bone marrow don’t mature into healthy blood cells. Sufferers of MDS go on to develop acute myeloid leukaemia (AML). The proprietary platform can generate multiple DiRs for specific genes suppressed in cancer and genetic conditions, re-establishing the pathway functionality. The first program, Aptadir Ce-49, is being developed in MDS and the aim is to enter the clinic by the end of 2025.
FinSMEs
24/09/2024